Pharma Investments, Ventures & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acromegaly
Recent studies from University of Antwerp add new data to acromegaly
March 2nd, 2008
According to recent research from Antwerp, Belgium, "Lanreotide-Autogel is a depot formulation of the somatostatin analog lanreotide used in the treatment of acromegaly. We investigated whether prolonging or shortening the interval between injections would offer any benefit." "The interval was prolonged from once every 4 weeks to once every 6 weeks when patients (n = 9) had normal IGF-I and GH concentrations. When patients (n = 12) had still elevated IGF-I or GH on the maximal dose of 1.20 mg every 4 weeks, the interval was shortened to once every 3 weeks. Serum IGF-I and GH were measured after 12 and 24 weeks to allow for dose adaptation. Symptoms and tumor volume were...
Source: Pharma Investments, Ventures & Law Weekly (2008-03-02)
|
